Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study
Clinical Breast Cancer · 2026-05 · 26 (5) · 75-82
DOI: 10.1016/j.clbc.2026.03.016 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Breast Cancer, 2026-05. Verfasst von Hideo Shigematsu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. Electronic address: s…. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Hiroshima University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION Clinical trials are evaluating axillary surgery de-escalation after neoadjuvant chemotherapy (NAC) in patients achieving a breast pathological complete response (pCR). We investigated ypN0 rates according to ypT stage in patients with cN+ breast cancer treated with NAC. MATERIALS AND METHODS We retrospectively analyzed 609 patients with cN+ breast cancer treated with NAC followed by surgery across 7 institutions. ypT was classified as ypT0, ypTis, or non-ypT0/Tis. Tumors were classified into biological subtypes based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. Logistic regression analysis was performed to identify factors associated with ypN0. The frequency of ypN0 was evaluated according to ypT stage, ycN, and tumor subtype. RESULTS Overall, ypN0 was achieved in 54.0% of patients. After NAC, 71.9% of patients were classified as ycN0, and ypT0, ypTis, and non-ypT0/Tis were observed in 21.5%, 10.3%, and 68.1% of patients, respectively. In multivariable analysis, ypT stage (ypT0: odds ratio [OR] 13.2; ypTis: OR 4.8), ycN0 (OR 4.5), HER2 positivity (OR 3.1), and HR negativity (OR 2.1) were independent predictors of ypN0. Among patients with ypT0 and ycN0, ypN0 rates exceeded 90%, reaching 97.1% in the HR-positive/HER2-positive subtype, 97.6% in the HR-negative/HER2-positive subtype, and 96.7% in the HR-negative/HER2-negative subtype. CONCLUSION A combination of ypT, ycN, and HR/HER2 status was strongly associated with ypN0 in patients with cN+ breast cancer. These findings represent a bridging study supporting risk stratification and the design of future trials evaluating axillary surgery omission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. Electronic address: shigematu1330@hiroshima-u.ac.jp.
- Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
- Department of Breast Surgery, JA Onomichi General Hospital, Hiroshima, Japan.
- Department of Breast and Endocrine Surgery, National Hospital Organization Higashihiroshima Medical Center, Hiroshima, Japan.
- Department of Gastroenterological, Breast and Transplant Surgery, Hiroshima Prefectural Hospital, Hiroshima, Japan.
- Department of Breast Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
Förderung
- Hiroshima University
Zitieren
APA
Shigematsu, H., Sasada, S., Amioka, A., Hashizume, J., Sasada, T., Goda, N., Hiraoka, E., Noma, M., Kawamata, A., Yoshiyama, T., Sueoka, S., Emi, A., Itagaki, T., Kajitani, K., & Okada, M. (2026). Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study. Clinical Breast Cancer, 26(5), 75-82. https://doi.org/10.1016/j.clbc.2026.03.016
Vancouver
Shigematsu H, Sasada S, Amioka A, Hashizume J, Sasada T, Goda N, et al. Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study. Clinical Breast Cancer. 2026;26(5):75-82. doi:10.1016/j.clbc.2026.03.016
BibTeX
@article{Shigematsu2026,
author = {Shigematsu, Hideo and Sasada, Shinsuke and Amioka, Ai and Hashizume, Junji and Sasada, Tatsunari and Goda, Noriko and Hiraoka, Emiko and Noma, Midori and Kawamata, Ayumi and Yoshiyama, Tomoyuki and Sueoka, Satoshi and Emi, Akiko and Itagaki, Tomoko and Kajitani, Keiko and Okada, Morihito},
title = {Combined ypT0 and ycN0 for Risk Stratification of ypN0 in Clinically Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A Multicenter Cohort Study},
journal = {Clinical Breast Cancer},
year = {2026},
volume = {26},
number = {5},
pages = {75--82},
doi = {10.1016/j.clbc.2026.03.016}
}
EUVIMED